{
    "clinical_study": {
        "@rank": "168082", 
        "arm_group": [
            {
                "arm_group_label": "Brivaracetam 10 mg oral tablet", 
                "arm_group_type": "Other", 
                "description": "Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 10 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.\nStrength: 10 mg\nForm: Oral tablet\nFrequency: Once daily\nDuration: 1 day"
            }, 
            {
                "arm_group_label": "Brivaracetam 50 mg oral tablet", 
                "arm_group_type": "Other", 
                "description": "Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 50 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.\nStrength: 50 mg\nForm: Oral tablet\nFrequency: Once daily\nDuration: 1 day"
            }, 
            {
                "arm_group_label": "Brivaracetam 75 mg oral tablet", 
                "arm_group_type": "Other", 
                "description": "Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 75 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.\nStrength: 75 mg\nForm: Oral tablet\nFrequency: Once daily\nDuration: 1 day"
            }, 
            {
                "arm_group_label": "Brivaracetam 100 mg oral tablet", 
                "arm_group_type": "Other", 
                "description": "Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 100 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.\nStrength: 100 mg\nForm: Oral tablet\nFrequency: Once daily\nDuration: 1 day"
            }, 
            {
                "arm_group_label": "10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)", 
                "arm_group_type": "Other", 
                "description": "Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of 10 mL of BRV intravenous bolus injection (10 mg/mL) will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.\nStrength: 100 mg (10 mg/mL)\nForm: Intravenous bolus injection\nFrequency: Once daily\nDuration: 1 day"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the bioavailability/bioequivalence of Brivaracetam oral tablets (10 mg, 50\n      mg, 75 mg and 100 mg) and Brivaracetam intravenous injection (100 mg) in healthy volunteers."
        }, 
        "brief_title": "Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is a healthy male or female volunteer aged 18-55 years inclusive\n\n          -  Subject has a Body Mass Index (BMI) of 18.0 - 30.0 kg/m^2 and a weight of at least 50\n             kg (males) or 45 kg (females)\n\n          -  Subject has normal vital signs values, Electrocardiograms (ECGs) and clinical\n             laboratory values\n\n          -  Female subjects should have a negative pregnancy test or be of non-childbearing\n             potential\n\n        Exclusion Criteria:\n\n          -  Volunteer has participated or is participating in any other clinical studies of\n             investigational drug or another Investigational Medicinal Product (IMP) within the\n             last 3 months\n\n          -  Volunteer is not healthy (eg, taking any drug treatments, excessive amount of\n             alcohol, cigarettes or caffeine, having any medical or emotional/psychological\n             problems, a drug/alcohol abuse, having abnormal safety parameters)\n\n          -  Subject has an intolerance or allergy against the compound or related drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796899", 
            "org_study_id": "EP0007", 
            "secondary_id": "2012-001358-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "Brivaracetam 10 mg oral tablet", 
                "intervention_name": "Brivaracetam 10 mg oral tablet", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Brivaracetam 50 mg oral tablet", 
                "intervention_name": "Brivaracetam 50 mg oral tablet", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Brivaracetam 75 mg oral tablet", 
                "intervention_name": "Brivaracetam 75 mg oral tablet", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Brivaracetam 100 mg oral tablet", 
                "intervention_name": "Brivaracetam 100 mg oral tablet", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)", 
                "intervention_name": "10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy Volunteers", 
            "Brivaracetam"
        ], 
        "lastchanged_date": "April 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands"
                }, 
                "name": "1"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Single-center, Open-label, 5-way Crossover, Single-dose Bioavailability/Bioequivalence Comparison of Brivaracetam Oral Tablets (10 mg, 50 mg,75 mg, and 100 mg) and Brivaracetam Intravenous Bolus Injection (100 mg) in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum plasma concentration of Brivaracetam dose-normalized to the 50 mg reference treatment (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification dose-normalized to the 50 mg reference treatment (AUC[0-t])", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from zero to infinity dose-normalized to the 50 mg reference treatment (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796899"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma half-life of Brivaracetam", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose"
            }, 
            {
                "measure": "Time to reach the maximum plasma concentration of Brivaracetam (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose"
            }, 
            {
                "measure": "Apparent oral clearance of Brivaracetam (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose"
            }, 
            {
                "measure": "Apparent volume of Brivaracetam distribution at the terminal elimination phase", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB Pharma SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}